NYMXF — Nymox Pharmaceutical Balance Sheet
0.000.00%
Last trade - 00:00- $3.78m
- $3.71m
Annual balance sheet for Nymox Pharmaceutical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 3.61 | 0.83 | 1.4 | 0.07 | 0.074 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.02 | 0.013 | 0.01 | 0.011 | 0.027 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 3.89 | 1.04 | 1.46 | 0.625 | 0.653 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.45 | 0.406 | 0.168 | 0.002 | 0.001 |
| Total Assets | 4.34 | 1.44 | 1.63 | 0.627 | 0.654 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.83 | 1.79 | 2.11 | 3.8 | 7.43 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 2.2 | 1.95 | 2.11 | 3.8 | 7.43 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 2.15 | -0.506 | -0.482 | -3.17 | -6.78 |
| Total Liabilities & Shareholders' Equity | 4.34 | 1.44 | 1.63 | 0.627 | 0.654 |
| Total Common Shares Outstanding |